在心脏消融导管评估中使用真实世界数据的可行性:国家卫生技术协调中心评估系统的试验案例。

IF 2.1 Q2 SURGERY BMJ Surgery Interventions Health Technologies Pub Date : 2021-12-09 eCollection Date: 2021-01-01 DOI:10.1136/bmjsit-2021-000089
Sanket S Dhruva, Guoqian Jiang, Amit A Doshi, Daniel J Friedman, Eric Brandt, Jiajing Chen, Joseph G Akar, Joseph S Ross, Keondae R Ervin, Kimberly Collison Farr, Nilay D Shah, Paul Coplan, Peter A Noseworthy, Shumin Zhang, Thomas Forsyth, Wade L Schulz, Yue Yu, Joseph P Drozda
{"title":"在心脏消融导管评估中使用真实世界数据的可行性:国家卫生技术协调中心评估系统的试验案例。","authors":"Sanket S Dhruva, Guoqian Jiang, Amit A Doshi, Daniel J Friedman, Eric Brandt, Jiajing Chen, Joseph G Akar, Joseph S Ross, Keondae R Ervin, Kimberly Collison Farr, Nilay D Shah, Paul Coplan, Peter A Noseworthy, Shumin Zhang, Thomas Forsyth, Wade L Schulz, Yue Yu, Joseph P Drozda","doi":"10.1136/bmjsit-2021-000089","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>To determine the feasibility of using real-world data to assess the safety and effectiveness of two cardiac ablation catheters for the treatment of persistent atrial fibrillation and ischaemic ventricular tachycardia.</p><p><strong>Design: </strong>Retrospective cohort.</p><p><strong>Setting: </strong>Three health systems in the USA.</p><p><strong>Participants: </strong>Patients receiving ablation with the two ablation catheters of interest at any of the three health systems.</p><p><strong>Main outcome measures: </strong>Feasibility of identifying the medical devices and participant populations of interest as well as the duration of follow-up and positive predictive values (PPVs) for serious safety (ischaemic stroke, acute heart failure and cardiac tamponade) and effectiveness (arrhythmia-related hospitalisation) clinical outcomes of interest compared with manual chart validation by clinicians.</p><p><strong>Results: </strong>Overall, the catheter of interest for treatment of persistent atrial fibrillation was used for 4280 ablations and the catheter of interest for ischaemic ventricular tachycardia was used 1516 times across the data available within the three health systems. The duration of patient follow-up in the three health systems ranged from 91% to 97% at ≥7 days, 89% to 96% at ≥30 days, 77% to 90% at ≥6 months and 66% to 84% at ≥1 year. PPVs were 63.4% for ischaemic stroke, 96.4% for acute heart failure, 100% at one health system for cardiac tamponade and 55.7% for arrhythmia-related hospitalisation.</p><p><strong>Conclusions: </strong>It is feasible to use real-world health system data to evaluate the safety and effectiveness of cardiac ablation catheters, though evaluations must consider the implications of variation in follow-up and endpoint ascertainment among health systems.</p>","PeriodicalId":33349,"journal":{"name":"BMJ Surgery Interventions Health Technologies","volume":null,"pages":null},"PeriodicalIF":2.1000,"publicationDate":"2021-12-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ce/79/bmjsit-2021-000089.PMC8749235.pdf","citationCount":"0","resultStr":"{\"title\":\"Feasibility of using real-world data in the evaluation of cardiac ablation catheters: a test-case of the National Evaluation System for Health Technology Coordinating Center.\",\"authors\":\"Sanket S Dhruva, Guoqian Jiang, Amit A Doshi, Daniel J Friedman, Eric Brandt, Jiajing Chen, Joseph G Akar, Joseph S Ross, Keondae R Ervin, Kimberly Collison Farr, Nilay D Shah, Paul Coplan, Peter A Noseworthy, Shumin Zhang, Thomas Forsyth, Wade L Schulz, Yue Yu, Joseph P Drozda\",\"doi\":\"10.1136/bmjsit-2021-000089\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objectives: </strong>To determine the feasibility of using real-world data to assess the safety and effectiveness of two cardiac ablation catheters for the treatment of persistent atrial fibrillation and ischaemic ventricular tachycardia.</p><p><strong>Design: </strong>Retrospective cohort.</p><p><strong>Setting: </strong>Three health systems in the USA.</p><p><strong>Participants: </strong>Patients receiving ablation with the two ablation catheters of interest at any of the three health systems.</p><p><strong>Main outcome measures: </strong>Feasibility of identifying the medical devices and participant populations of interest as well as the duration of follow-up and positive predictive values (PPVs) for serious safety (ischaemic stroke, acute heart failure and cardiac tamponade) and effectiveness (arrhythmia-related hospitalisation) clinical outcomes of interest compared with manual chart validation by clinicians.</p><p><strong>Results: </strong>Overall, the catheter of interest for treatment of persistent atrial fibrillation was used for 4280 ablations and the catheter of interest for ischaemic ventricular tachycardia was used 1516 times across the data available within the three health systems. The duration of patient follow-up in the three health systems ranged from 91% to 97% at ≥7 days, 89% to 96% at ≥30 days, 77% to 90% at ≥6 months and 66% to 84% at ≥1 year. PPVs were 63.4% for ischaemic stroke, 96.4% for acute heart failure, 100% at one health system for cardiac tamponade and 55.7% for arrhythmia-related hospitalisation.</p><p><strong>Conclusions: </strong>It is feasible to use real-world health system data to evaluate the safety and effectiveness of cardiac ablation catheters, though evaluations must consider the implications of variation in follow-up and endpoint ascertainment among health systems.</p>\",\"PeriodicalId\":33349,\"journal\":{\"name\":\"BMJ Surgery Interventions Health Technologies\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":2.1000,\"publicationDate\":\"2021-12-09\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ce/79/bmjsit-2021-000089.PMC8749235.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"BMJ Surgery Interventions Health Technologies\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1136/bmjsit-2021-000089\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2021/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"SURGERY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMJ Surgery Interventions Health Technologies","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1136/bmjsit-2021-000089","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"SURGERY","Score":null,"Total":0}
引用次数: 0

摘要

目的确定使用真实世界数据评估两种心脏消融导管治疗持续性心房颤动和缺血性室性心动过速的安全性和有效性的可行性:设计:回顾性队列:地点:美国三个医疗系统:主要结果指标:识别医疗器械的可行性:主要结果测量指标:与临床医生手动图表验证相比,确定相关医疗设备和参与人群的可行性,以及随访时间和严重安全性(缺血性中风、急性心力衰竭和心脏填塞)和有效性(心律失常相关住院)临床结果的阳性预测值(PPV):总体而言,在三个医疗系统的现有数据中,用于治疗持续性房颤的相关导管共进行了 4280 次消融,用于治疗缺血性室性心动过速的相关导管共进行了 1516 次消融。三个医疗系统的患者随访时间分别为:≥7 天 91% 至 97%,≥30 天 89% 至 96%,≥6 个月 77% 至 90%,≥1 年 66% 至 84%。缺血性中风的 PPV 为 63.4%,急性心力衰竭的 PPV 为 96.4%,在一个医疗系统中,心脏填塞的 PPV 为 100%,心律失常相关住院的 PPV 为 55.7%:结论:使用真实医疗系统数据评估心脏消融导管的安全性和有效性是可行的,但评估必须考虑医疗系统间随访和终点确定的差异所带来的影响。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

摘要图片

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Feasibility of using real-world data in the evaluation of cardiac ablation catheters: a test-case of the National Evaluation System for Health Technology Coordinating Center.

Objectives: To determine the feasibility of using real-world data to assess the safety and effectiveness of two cardiac ablation catheters for the treatment of persistent atrial fibrillation and ischaemic ventricular tachycardia.

Design: Retrospective cohort.

Setting: Three health systems in the USA.

Participants: Patients receiving ablation with the two ablation catheters of interest at any of the three health systems.

Main outcome measures: Feasibility of identifying the medical devices and participant populations of interest as well as the duration of follow-up and positive predictive values (PPVs) for serious safety (ischaemic stroke, acute heart failure and cardiac tamponade) and effectiveness (arrhythmia-related hospitalisation) clinical outcomes of interest compared with manual chart validation by clinicians.

Results: Overall, the catheter of interest for treatment of persistent atrial fibrillation was used for 4280 ablations and the catheter of interest for ischaemic ventricular tachycardia was used 1516 times across the data available within the three health systems. The duration of patient follow-up in the three health systems ranged from 91% to 97% at ≥7 days, 89% to 96% at ≥30 days, 77% to 90% at ≥6 months and 66% to 84% at ≥1 year. PPVs were 63.4% for ischaemic stroke, 96.4% for acute heart failure, 100% at one health system for cardiac tamponade and 55.7% for arrhythmia-related hospitalisation.

Conclusions: It is feasible to use real-world health system data to evaluate the safety and effectiveness of cardiac ablation catheters, though evaluations must consider the implications of variation in follow-up and endpoint ascertainment among health systems.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
2.80
自引率
0.00%
发文量
22
审稿时长
17 weeks
期刊最新文献
The impact of adjuvant antibiotic hydrogel application on the primary stability of uncemented hip stems. Prospective randomized evaluation of the sustained impact of assistive artificial intelligence on anesthetists' ultrasound scanning for regional anesthesia. Clinical effectiveness of a modified muscle sparing posterior technique compared with a standard lateral approach in hip hemiarthroplasty for displaced intracapsular fractures (HemiSPAIRE): a multicenter, parallel-group, randomized controlled trial. IDEAL evaluation for global surgery innovation. No frugal innovation without frugal evaluation: the Global IDEAL Sub-Framework.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1